Hey ,
Oppenheimer turns bullish on Comcast catalysts
“A big player stepped in and scooped up every contract they could get their hands on these $46 calls at $0.34.”
I don’t have any family and friends that work at Oppenheimer. I didn’t need it, all I needed was the Dollar Ace scanner.
Do you really think that the bank will jeopardize that relationship by having one of its analysts come out and give a SELL recommendation?
Of course, in theory, none of this is supposed to matter. That’s because banks set up “Chinese Walls” to eliminate the conflict of interest between them and the analysts.
I have chosen the latter. And you should too. My Dollar Ace service stalks the biggest, baddest, and most profitable options traders in the world. My scanner tells me what they’re trading, how much they are expecting the stock to move by, and by when.
Cheers to Profits! ![]() Kyle Dennis
RagingBull, LLC Neither Kyle Dennis nor RagingBull.com, LLC (publisher of BiotechBreakouts) is registered as an investment adviser nor a broker/dealer with either the U. S. Securities & Exchange Commission or any state securities regulatory authority. Users of this website are advised that all information presented on this website is solely for informational purposes, is not intended to be used as a personalized investment recommendation, and is not attuned to any specific portfolio or to any user's particular investment needs or objectives. The owners, employees and writers of RagingBull.com may engage in securities trading that is discussed or viewed on this website, but all such individuals are buying and selling such securities for their own account. These individuals do not engage in any trades with customers. The buying and selling of securities by these individuals is not part of a regular business of buying and selling securities. Past performance is NOT indicative of future results. Furthermore, such information is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell (short or otherwise) any security. All users of this website must determine for themselves what specific investments to make or not make and are urged to consult with their own independent financial advisors with respect to any investment decision. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. All opinions, analyses and information included on this website are based on sources believed to be reliable and written in good faith, but should be independently verified, and no representation or warranty of any kind, express or implied, is made, including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. In addition, we undertake no responsibility to notify such opinions, analyses or information or to keep such opinions, analyses or information current. Also be aware that owners, employees and writers of and for RagingBull.com, LLC may have long or short positions in securities that may be discussed on this website or newsletter, but all such positions are held for such representative’s own account. Past results are not indicative of future profits. This table is accurate, though not every trade is represented. Profits and losses reported are actual figures from the portfolios Kyle Dennis manages on behalf of RagingBull.com, LLC. If you have a current active subscription with Biotech Breakouts you will need to contact us here if you want to cancel your subscription. Opting out of emails does not remove you from your service at BiotechBreakouts.com. |
Home
› Uncategorized




Post a Comment
Post a Comment